Uncategorized

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

Fulcrum’s setback is the latest in a series of stumbles for the developers of sickle cell medicines, among them Pfizer, Novartis and Intellia Therapeutics.

Read More

Published

on

Fulcrum’s setback is the latest in a series of stumbles for the developers of sickle cell medicines, among them Pfizer, Novartis and Intellia Therapeutics.

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version